REG-Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Genmab presented updated Phase 2 follow-up analyses of petosemtamab plus FOLFOX/FOLFIRI in metastatic colorectal cancer at the ESMO Congress 2026. Confirmed and unconfirmed objective response rates were 75% in first-line and 67% in second-line patients, rising to 81% in 1L patients with left-sided tumors, and most previously unconfirmed responses were confirmed with longer follow-up. Safety was manageable, with discontinuations due to petosemtamab-related TEAEs in 5% (FOLFOX) and 3% (FOLFIRI) of patients and no treatment-emergent deaths.
Key figures
- Drug Name
- petosemtamab (GEN1158)
- Phase Of Trial
- Phase 2
- Orr 1 L
- 75%
- Orr 2 L
- 67%
- Patients treated
- 79
- Orr 1 L left sided
- 81%
- Disease control rate 1 L
- 95%
- Disease control rate 2 L
- 93%
- Median followup 1 L months
- 5.9
- Median followup 2 L months
- 7.1
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.